

# Acronym for cohort: LeARN (WP4)

<https://neurodegenerationresearch.eu/survey/acronym-for-cohort-learn-wp4/>

## Title of the cohort

## Acronym for cohort

LeARN (WP4)

## Name of Principal Investigator

Title            prof. dr.

First name    Frans

Last name     Verhey

## Address of institution where award is held

Institution     Alzheimer Center Limburg

Street Address Dr. Tanslaan 12

City             Maastricht

Postcode       6229 ET

## Country

Netherlands

## Website

[www.alzheimercentrumlimburg.nl](http://www.alzheimercentrumlimburg.nl)

## Contact email

[p.aalten@maastrichtuniversity.nl](mailto:p.aalten@maastrichtuniversity.nl)

## Funding source

Government, industry and universities

## 1. The cohort includes, or expects to include, incidence of the following conditions

Alzheimer's disease and other dementias

## When studies on the above condition(s) are expected to become possible

2011 – 2015

## 2a. Stated aim of the cohort

## 2b. Features distinguishing this cohort from other population cohorts

## 3a. i) Number of publications that involve use of cohort to date

0

## 3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

## 3b. Publication list/link to where data or publications are accessible (if available)

## 3c. Information (i.e. research findings) expected to be gained from the population cohort

## 4a. Study criteria: age range of participants at recruitment

Age in years from: 55

To ('until death' if applicable):

**4b. Study criteria: inclusion criteria**

**4c. Study criteria: exclusion criteria**

**5. Size of the cohort (i.e. number of participants enrolled)**

1,000 – 5,000 participants

**6a. Measures used to characterise participants**

Demographic data, clinical data, Mini Mental State Examination, Clinical Dementia Rating Scale, Neuropsychiatric Inventory, Disability Assessment for Dementia Scale, Geriatric Depression Scale, EuroQol-5D

**6b. Additional measures for participants with a clinical disorder**

MRI (including DTI and resting state fMRI), PET (FDG and PiB-PET), CSF

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

No

**7. Study design**

- Prospective cohort

**8. Cases matched by**

- Cognitive function

**9a. Does the study include a specialised subset of control participants**

Yes

**9b. If yes, description of specialised subset of control participants**

Patients with only subjective memory complaints will be controls for patients with objective memory complaints

**10a. i) Data collection start date**

01-11-2009

**10a. ii) Data collection end date**

01-05-2011

**10a iii) Data collection for this study is**

Data analysis ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

Yes – intend to apply for funding

**11. Data collected**

Only through the study

**12. System in place to enable re-contact with patients for future studies**

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

Yes/No % available

Data summarised in database yes 100

Database is web-based yes 100

Database on spreadsheet yes 100

Database is on paper yes 100

Other (specify)

**Language used:**

Dutch

**13b. Format and availability of data held as individual records**

Yes/No % available

Data held as individual records yes 100

Data is web-based yes 100

Data held on computer based records yes 100

Data held on cards no

Other (specify)

**Language used:**

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Apply to PI or co-ordinator at resource

**15. Data sharing policy specified as a condition of use**

Data made publicly available after a specified time point

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: cerebro-spinal fluid

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Primary Samples: Stabilised samples (frozen or fixed)

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**

- Yes, for all the cohort